GlassScriptPhysician profile
Katherine M Zuber
NPI 1396386967
$6,383.15
in general payments reported to CMS, 2019-2025
33 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,495 · 2022: $1,602 · 2023: $2,150 · 2024: $833 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,088 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,088.46 |
| Education | $197.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,189.43 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $730.60 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $449.46 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $368.47 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $351.26 | 2021-2023 | |
| Amgen INC. | $348.31 | 2021-2024 | Evenity, Prolia, Repatha |
| Medtronic, INC. | $336.03 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $267.88 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.50 | 2021-2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $227.69 | 2021-2024 | Strensiq |
| Amryt Pharma Holdings LTD | $219.97 | 2021-2023 | Mycapssa |
| Tandem Diabetes Care, INC. | $201.17 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $163.42 | 2021 | |
| Corcept Therapeutics | $162.29 | 2022-2023 | Korlym |
| Astellas Pharma US INC | $130.60 | 2023 | Veozah |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $116.27 | 2021-2024 | Dexcom G6 Transmitter |
| Zealand Pharma US, INC. | $105.57 | 2021-2022 | |
| Esperion Therapeutics, INC. | $98.30 | 2021-2024 | Nexletol |
| Amarin Pharma, INC. | $92.48 | 2021 | |
| Chiasma, INC. | $88.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $67.50 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $64.66 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $55.82 | 2022 | |
| Radius Health, INC. | $49.96 | 2022 | |
| Lifescan, INC. | $47.51 | 2021-2022 | |
| Horizon Therapeutics Plc | $47.09 | 2023 | Tepezza |
| Kyowa Kirin, INC. | $43.32 | 2023-2024 | Crysvita |
| Eusa Pharma (US) LLC | $40.35 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.13 | 2021 | |
| Pfizer INC. | $16.13 | 2023 | |
| Abbvie INC. | $14.55 | 2021 | |
| Alfasigma USA, INC. | $14.01 | 2022 | |
| Echosens North America, INC. | $13.78 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Zuber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.